ASCO Introduces Two New Journals: JCO Precision Oncology and JCO Clinical Cancer Informatics
ASCO is excited to launch two new online-only journals, JCO Precision Oncology (JCO PO) and JCO Clinical Cancer Informatics (JCO CCI). Both journals will be exploring the latest topics in oncology and filling a void for the oncology community. Manuscripts will go through the traditional peer-review process, but unlike ASCO’s other publications, JCO PO and JCO CCI will be published using a continuous publishing model. This workflow allows articles to be published individually as soon as they are ready, rather than waiting to be compiled into an issue, which will help facilitate faster publication and citations as well as coincide with the current trends from print to publication.
JCO Precision Oncology
JCO PO will publish research that will advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer. Innovative and timely scientific and educational content will provide a deeper understanding of actionable cancer genomics; personalized translational and clinical oncology research; and recent treatment advances based on tumor molecular profiling. The scope of publications will include all types of clinical research (basket trials, exceptional response results, informatics, mechanism and evidence-based case reports, and small series of educational value), and extensive expert-driven commentary, editorials, and reviews considering the challenges and value of targeted therapies based on genomic analyses.
James M. Ford, MD, will serve as founding Editor-in-Chief of JCO PO. Dr. Ford is an Associate Professor of Medicine (Oncology), Pediatrics (Medical Genetics) and Genetics, and Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford Cancer Institute. His research is dedicated to studying the genetic basis of breast and gastrointestinal cancer development and the role of DNA repair in the treatment and prevention of cancer in families and populations. Dr. Ford is joined by six founding Associate Editors and a 22-member editorial board with a wide range of multidisciplinary expertise and a wealth of experience.
JCO Clinical Cancer Informatics
JCO CCI will publish research on biomedical informatics methods and processes applied to cancer-related data and images. The journal will strive to bridge the gap between clinical oncology and data science, seeking papers that advance the development, interpretation, and clinical application of cancer informatics research and how to engineer better systems of care delivery. Article types of interest include original research, editorials, and commentaries reporting on biomedical informatics studies relevant to cancer treatment, care delivery, outcomes, and prevention.
Debra Patt, MD, MPH, MBA, will be leading a team of nine Associate Editors as Editor-in-Chief of JCO CCI. All Associate Editors have unique expertise that they can bring to the journal to enhance the publication. Dr. Patt specializes in medical oncology and hematology, is Vice President of Texas Oncology, and Medical Director of Outcomes Research and the Pathways Task Force for The US Oncology Network. Her primary research interests are in health services research, health economics outcomes research, and health policy. The journal also has a robust editorial board with 27 members.
ASCO cannot wait to share these two new journals with you. Both journals will offer a unique opportunity to have your precision oncology and informatics research make an impact on cancer care delivery and research via the unparalleled reach and reputation of ASCO. Articles will start posting online late 2016 and early 2017. To find more information about the journals and learn how to submit a manuscript, visit http://po.jco.org/ for JCO PO and http://cci.jco.org/ for JCO CCI. ■
© 2016. American Society of Clinical Oncology. All rights reserved.